INNOVATIVE RESEARCH OF AMERICA
`
`H"!
`
`Most scientists agree that the three essential parameters in the success of a biomedical
`experiment are:
`
`A. The scientific problem formulated in a defined question.
`
`B. The laboratory animal, healthy and untraumatized.
`
`C. The process of active product delivery; the most problematic variable of all three!
`
`For a third of a century, Innovative Research of America has assumed the leadership role
`
`in improved time release technology. The main mission is to standardize the technology of
`
`drug delivery. Our proven Time Release Hormone and Drug Pellets help investigators take
`
`charge of product delivery and expand their abilities to do meaningful and reproducible
`
`research.
`
`ADVANTAGES OF THE PELLET DELIVERY SYSTEM
`
`
`.1--'8} coni;.é1iii%:iit-l€wi:ig'-tr$iiEir-
`
` l - atready-teradministerp_e1_1et"-zfor it
`
`
`.cic>t‘1trti:»:'Ii_1:c§:i1:- " I
`
`
`
`A a qepssqabrse -way.td'_in9_iiiii_riiiz_e=. as
`
`551136115 "5*jiI3r?=:'r'*?'>"Et‘:'_f'.=l,1i ffiriséitiiiifibifilvssan .isssrepi?r$ds°1 -
`
`s U
`
`shering In The Age Oflmiovative Research
`
`I
`
`Astrazeneca Ex. 2044 p. 2
`
`

`
`HORMONE AND DRUG PELLETS FOR BIOMEDICAL RESEARCH
`
`Since it is not easy to administer drugs and hormones orally to research animals,
`
`several delivery methods have been devised as alternatives. However, most scientists
`
`continue to labor with unreliable injectables to conduct their research.
`
`Because of this inadequacy, biomedical research is as confusing as it is challenging
`
`and as frustrating as it is creative. The options of scientists to address scientific questions
`
`are not only dependent, but are also limited by the process of active product delivery.
`
`Traditionally, product delivery into the experimental animal has been the procedure most
`
`subject to variables and the most difficult to standardize effectively. The very process
`
`of having to accurately administer drugs to experimental animals can become a logistic
`
`nightmare for scientists.
`
`CHANGING THE TIME COURSE OF DRUG DELIVERY
`
`We Tell Tiiiic-Rclcauc l’c1l-cts W]_i:1tTi1iic It is
`
`Astraleneca Ex. 2044 p. 3
`
`

`
`IRA TABLE OF CONTENTS
`
`Find a Product in this Catalog ........................................................ .. 5
`
`Ordering Information I General Policy 8. Terms ............. .. 6, 7, 44, 84
`
`Sales of Anabolic Steroids ............................................................. .. 8
`
`Category Index.......................................................................... .. 10-15
`
`Alkaioids
`Amino Acids
`Androgens
`Antibiotics
`Anti-Inflammatory Agents
`Anti—NeopIastics
`Catecholarnines
`Corticoids and Diuretics
`
`Estrogens
`Fatty Acids
`Nucleotide Related Products
`Progestins
`Prostaglandins
`Thyroids
`Vitamins
`
`Placebo Pellets information I Price Schedules...
`
`Alphabetical Product Listing ................................................... .. 21-42
`
`Stock Pellet Price Schedules ................................................... .. 45-71
`
`Pellets for lmmuno-Deficient Mice
`
`17B-Estradiol [Tamoxifen 8: Sample References ................... .. 73-77
`
`Androgens I Anti-Androgens 8: Sample References ............. .. 78-80
`
`Trochar & Recommended Implantation Procedure ...............81, 123
`
`Doxycycline &Tetracycline Pellets in Mice .............................. 85-86
`
`Hormone + Hormone Pellets ................................................... .. 89-92
`
`Custom Pellets ........................................................................ .. 934 08
`
`Selected References ............................................................. ..109-122
`
`Order Forms ............................................................ .. Back of Catalo -
`
`Patents ................................................................. .. inside Back Cover
`
`*Forfun‘her assistance, view our website at:
`wwwjnnovrsrch. com
`
`W‘-c Add Time To ‘Your Day
`
`Astrazencca Ex. 2044 p. 4
`
`

`
`PRODUCT DESIGN AND FEATURES
`
`
`
`The Pellet Implantation Methodology provides solutions to:
`
`consistency in timing repeated product administrations.
`
`controlling the amount of product administered.
`
`stability of the product preparation.
`
`safety of the experimenter.
`
`neurophysiological trauma to the animal from excessive handling.
`
`freeing valuable research time.
`
`eliminating unnecessary and unstimulating laboratory practices.
`
`Scientists from several research disciplines have documented in scientific literature that
`
`our Pellet Delivery System is effective, consistent, reproducible, economical, reliable, and
`
`safe for the animal. See Selected References on pages 109- 122.
`
`On] Time Release Pellets Really-* Kmzfm.-' Wlmi Time II ls
`
`Astrazeneca Ex. 2044 p. 5
`
`

`
`PRODUCT SPECIFICATIONS
`
`
`AVAILABLE SHAPES AND SIZES
`
`Stock pellets are round and range in diameter from N8” (3 mm) to H2” (1.25 cm) depending on the
`dose and the release rate. Our Custom Pellets Department will also design various pellet shapes and
`smaller sizes (Page 94) to meet your research needs. Please refer to the Custom Pellets section on pages
`93-103.
`
`AVAILABLE DOSAGES
`
`Most of the stock products in this catalog are available in 20 different dosages ranging from 1 rnicrogram
`(0.001 mg) per pellet up to 200 milligrams (200 mg) per pellet within the specified release rate. Doses of
`pellets listed in this catalog reflect the total amount of net active product released over the indicated
`period of time.
`
`AVAILABLE RELEASE. RATES
`
`Stock products are designed to release continuously for 21 days, 60 days, or 90 days. Please refer to our
`Custom Pellets section on pages 93-108 for other release rates tailored for the duration of the experiment.
`
`AVAILABLE PRODUCTS
`
`In our continuing quest to make available new stock items that are particularly in demand, we have added
`several products to the original categories. In addition to the listed pelletized products, Innovative
`Research of America has an efficient Custom Pellets Department to prepare products that are not available
`as stock items.
`
`SELECTED REFERENCES
`
`A sample of publications that employed our delivery system in a broad spectrum of products can be found
`on pages 109—122.
`
`Consistent Dose-Dependent Release
`
`Astrazeneca Ex. 2044 p. 6
`
`

`
`FINDING A PRODUCT IN THIS CATALOG
`
`The PRODUCTS in this catalog are arranged in ALPHABETICAL ORDER and are identified by
`a CATALOG NUMBER and 21 PRICE SCHEDULE with a PAGE NUMBER.
`
`The catalog number and price schedule reflect a release rate of 21 days. 60 days, or 90 days.
`
`To illustrate with 173-Estradiol as an example:
`
`EXAMPLE
`
`Product
`
`21-Day Release
`Catalog
`Price Schedule!
`Number
`Page Number
`
`60-Day Release
`Catalog
`Price Scheduled
`Number
`Page Number
`
`90-Day Release
`Catalog
`Price Schedule)’
`Number
`Page Number
`
`
`
`173 - Eslradiol
`
`E - I21
`
`B-21:’48
`
`SE - 121
`
`B-60149
`
`NE- 121
`
`B—90J'50
`
`
`
`The above example indicates that 1713-Estradiol is available in three release forms each having a
`
`different catalog number and price code, i.e.
`
`E - 121 is a 21-day release form with a price code of B-21, found on page 48.
`
`SE - 121 is a 60-day release form with a price code of B-60, found on page 49.
`
`NE - 121 is a 90-day release form with a price code of B-90, found on page 50.
`
`The PAGE NUMBER next to the PRICE SCHEDULE indicates the page where the actual price
`
`for the product appears.
`
`When ordering please use the PRODUCT NAME, CATALOG NUNIBER, RELEASE
`
`RATE and DOSE. Most products are available in 20 different dosages. Products are sold in
`
`Lots of 25. 50. I00, and 200 pellets. Please indicate the quantity of pellets being ordered.
`
`Beginning on Page 10 we have grouped some of our catalog items in related categories
`
`alphabetically. We hope the listing will help in noting items of potential interest.
`
`Tinte-Release Pellets... Alu--aye On Time
`
`Astrazeneca Ex. 2044 p. 7
`
`

`
`
`
`° Mail
`
`0 Internet I E-Mail
`
`Innovative Research of America, Inc.
`2 North Tamiamj T1-aj]
`
`httpfifwww-innovrsrch-com (website)
`pellets@innovrsrch.corn (e-mail)
`
`Suite 404
`
`Sarasota, Florida 34236 USA
`
`- Phone
`
`(941) 365-1406
`
`(941) 365-1506
`(300) 4213171 (USA/Canada)
`
`* Fax
`
`(941) 365-1703
`
`(941) 365-1803
`
`(800) 643-4345 (USA/Canada)
`
`(800)648-6030 (USA/Canada)
`
`IRA’s website features our company profile,
`the latest product technology and on—line ordering.
`
`AMERICAN EXPRESS
`VISA AND MASTERCARD ACCEPTED.
`Purchase Order Forms are in the back of the
`
`catalog.
`
`
`
`Custom Pellets Information Form on page 95.
`
`Bank Wire Payment Information
`Payment via bank wire should be directed as follows."
`
`THE DWFEKENCE ES
`cousrsrewcv AND umrormrrr.
`
`
`
`“““"“““*
`1300 Second 31., Suite 100
`Sarasota, Florida 34236
`Routing 1‘? (ABA) 26319 I 33‘?
`Electronic Tlransfers it 263 W138?
`
`II1 favor of:
`Innovative Research of America
`2 North Tamiami Trail
`Suite 404
`
`Sarasota. FL 34236
`
`Checldng Account: #0C|00l473l6l54
`Swift Code: BRBTUS33
`
`Ushering In The Age Of Irrnox-‘am-‘e R(3Sr'3fll‘L'.'l1
`
`Astrazeneca Ex. 2044 p. 8
`
`

`
`

`
`SALE OF CONTROLLED ANABOLIC STEROIDS
`
`within the United States
`
`
`(Telephone orders will not be accepted - orders 8: copy of DEA license may be mailed or faxed)
`
`Before we can prepare any orders of Anabolic Steroid Pellets, the Drug
`
`Enforcement Administration (DEA) requires us to obtain: '
`
`1. A valid photocopy of the investigator’s DEA Registration
`
`containing Schedule 3N.
`
`2. A written Purchase Order showing the investigator’s DEA
`
`Registration Number and proper shipping address.
`
`CONTACT INNOVATIVE RESEARCH OF AMERICA
`
`BY PHONE. MAIL, FAX OR E-MAIL
`FOR MORE ORDERING INFORMATION - SEE PAGE 6
`
`SALE OF CONTROLLED ANABOLIC STEROIDS
`
`outside the United States (International)
`
`
`WE NO LONGER SHIP ANABOLIC STEROIDS
`
`outside the United States (International)
`
`DEA Controlled Anabolic Steroids
`
`Androstenediol
`
`l9—Nortestosterone 17-Decanoate
`
`Androstenedione
`
`19-Nortestosterone l7-Dipropionate
`
`5ot—Dihydrotestosteror1e
`
`Fluoxymesterone
`
`Mesterolonc
`
`Mesterone
`
`Methandriol
`
`Methandriol Dipropionate
`
`Stanozolol
`
`Testosterone
`
`Testosterone Acetate
`
`Testosterone Benzoate
`
`Testosterone Cypionate
`
`Testosterone Enanthate
`
`19~No1‘testosterone
`
`Testosterone I 7!!»-Hemisuccinate
`
`,;-I
`
`Testosterone Propionate
`
`Alwaj,»'s On Time
`
`Time Release Pellets
`
`Astrazeneca Ex. 2044 p. 10
`
`

`
`VIJ
`
`T4
`
`See pages 73-80 regarding
`Hormone/Anti—Horm0ne products
`for Immune-Deficient Mice
`
`and specific references.
`
`Y0u1'Rcscarch Time Is U11dc.r Your Comm]
`
`Astrazeneca Ex. 2044 p.
`
`1 1
`
`

`
`

`
`

`
`

`
`

`
`

`
`

`
`ADVANTAGES OF OUR MDD PELLET SYSTEM A
`
`ii
`
`9 Saves time
`
`0 Ready-to-implant
`
`9
`
`insures controlled product release over time
`
`. Avoids “peak and valley” effects
`
`0 Guarantees consistent product preparation
`
`0 Extends product life against spontaneous breakdown
`
`9 Extends product life against host-related breakdown
`
`0 Minimizes experimental variables
`
`0
`
`lnsures safety of the researcher
`
`or Reduces neurophysiological trauma to the animal!
`
`no =-"cessive handling
`
`9 Generates more meaningful and reproducible results
`
`0 Superior to conventional delivery methods
`
`0 Enhances experimental efficiency
`
`9 Frees valuable time for creative research
`
`. Saves money
`
`Timc~Releas;c Pcllcts... AiW’£'l},-’S On Time
`
`Astrazeneca Ex. 2044 p. 18
`
`

`
`
`
` PLACEBO / CONTROL
`PELLETS
`
`
`Matching Placebo pellets contain all the components of the hormone or drug pellet except the active
`product itself. The carrier-binder excepients of the matrix include Cholesterol, Lactose, Celluloses,
`Phosphates and Stearates.
`
`Stock Placebo pellets are available in 2|} different doses corresponding to those of active pmduct
`pellets. Each dose is offered in either 21 Day, 60 Day, or 90 Day Release form.
`
`Although the matrixes in Placebo pellets have a different composition for different active products,
`they are all assigned the same catalog number and are offered at the same price schedule.
`
`When inquiring or placing an order, please specify the active product you wish to correspond the
`Placebo pellets for. Please see the following examples:
`
`Catalog No.
`
`Dc..scripl'io.n
`
`Dose in Itlg.-‘pellet
`
`Release in Days
`
`90 Day
`
`C-11 1
`
`SC—l 11
`
`Placebo for "Active Product”*
`
`Placebo for “Active Product”
`
`j mgfpellet
`
`_: mgfpellet
`
`21 Day
`
`60 Day
`
`NC-111
`
`Placebo for “Active Product”
`
`mgfpellet
`
`*In place of “Active Product” specify the hormone or drug you are utilizing in your study.
`
`The following three pages are universal dose {price schedules in all three release rates (21 Day, 60
`Day, and 90 Day) and are applicable as a matching Placebo for all products in the catalog except
`special physical size and preparations (page 94) which can be found under the Custom Pellet section
`on pages 93-108.
`
`*Please inquire directly with as tffurther assistance is required regarding a product ofinterest.
`
`
`
`Astrazeneca Ex. 2044 p. 19
`
`

`
`'1}!
`
`
`
`Astrazeneca Ex. 2044 p. 20
`
`

`
`
`
` $697
`
`15
`
`10D
`
`150
`
`25E
`
`35E
`
`50E
`
`75D
`
`100D
`
`1500
`
`$697
`
`$697
`
`$697
`
`$697
`
`$697
`
`$697
`
`$702
`
`$702
`
`$702
`
`$70?
`
`$?D?
`
`$707
`
`$?0?
`
`$718
`
`$718
`
`2000
`
`$723
`
`A combination of multiple dosages in one lot, for any specified product, is also
`available. PLEASE INQUIRE.
`
`Sixty and Ninety day price schedules are on the following two pages.
`
`
`
`AstraZeneca Ex. 2044 p. 21
`
`

`
`
`
` J1
`
`PRICE SCHEDULE
`
`Cat. No. SC—1 11
`
`A combination of multiple dosages in one lot, for any specified product, is also
`available. PLEASE INQUIRE.
`
`
`
`Astrazeneca Ex. 2044 p. 22
`
`

`
`—-'-1
`
`—_-.?_— .§_.,t'.-i--
`
`.-.-
`
`-u_._,-__--..
`
`-
`
`_
`
`¢-_:~-v».—.wv-—-r3_'_-1.-_:--i-7-2u_- :".'.‘
`
`.._.....-...:..-..-.-.'...n.._......._...__....—-'-......"........'-' ._-.:.';'.':.:.'.__.-J
`
`1
`
`-.;_—'-'-tfi:-vgu-:r-I-~1s-:r::r;::?-fl’--:r-r~—r°e=~,7'*5‘_'1%?‘C‘F'7'T?r:r1jrr-T--_-3+-—~.«-<f.
`
`PRICE SCHEDULE
`
`A combination of multiple dosages in one lot, for any specified product, is also
`available. PLEASE INQUIRE.
`
`
`
`Astrazeneoa Ex. 2044 p. 23
`
`

`
`TIME RELEASE PELLETS FOR
`
`BIOMEDICAL RESEARCH IN
`
`LABORATORY ANIMALS
`
`Pain‘:
`
`0ne{Sf§:ij.
`
`Eelease Pellets Are'_t_h'e Best Alte__t‘fiEtive
`Time Iielease Pellets
`for Biomedical Research from IRA
`DOSE
`
`PELLETS
`
`FOR
`
`O)))))))))))))))))))
`
`RELEASE
`
`O))))))))))))))
`O))))))))))))
`
`Our Team a1.‘IRA is working
`
`to meet the responsibility that
`
`Innovative Science demands
`
`and Innovative Scientists
`
`deserve.
`
`Astrazeneca Ex. 2044 p. 24
`
`

`
`

`
`
`
`Astrazeneca Ex. 2044 p. 26
`
`

`
`ALPHABETICAL PRODUCT LISTING
`
`DosefI’rice Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`Pmdnct
`
`Acebulolol
`
`.-
`
`21-Day Release 60-Day Release
`(_.‘;|l;I1n;_'_ Price Sciledllitf
`C'.i't:1|I>,t_:
`I"ri|.'t‘
`."\'cl1I:dl:|e.I'
`Nunlhur P::g1-
`-'\'IImh|.-1‘
`Ninlllavr Pngl‘ NlI:'nf_lI'r
`
`90-Day Release
`fi‘.a1aI+.>p_ Price 5E'ht'(il1Itu'
`Nllnllwl’ I"'.Ig|'
`_\'lm1|':eJ’
`
`C-101
`
`NC-1 U1
`
`B-90150
`
`B-90150
`
`N-Acetyiimidazole
`
`cis-Aconitic Acid
`
`C~60!52
`
`B-50149
`
`B-60;'49
`
`B-60;'49
`
`'.".3f*5.""*'5§:-_': _.
`B-60!49
`
`“A
`
`J
`
`B-60J'49
`
`D-60:’55
`
`Astrazeneca Ex. 2044 p. 27
`
`

`
`21-Day Release
`C:%i;!ll)L',
`l’rii:e .‘n:hedtt[1.'.I'
`Numl_:r:r
`P:-!]_._EL’
`§\'Lm1|N:r
`
`60-Day Release
`Cm'.11Lng I-‘rice
`.ԤchI:'r'Eutt=.I'
`Nulnher Paige
`!VuII:IJL':'
`
`90-Day Release
`C:i1'.uI«..I:{ 'l"ria.'L‘ Scheduh-.i
`Numher Palgt Numlnzr
`
`.. _
`
`_
`
`.
`
`_
`
`Arncinonide
`
`-f.__3: ;
`h§m§n£:'§¢él§fiit}i':é' H I
`
`fl -éi5;'¥:ri{_i;i§ééétébhé'non¢
`m-Aminoacetoglnherlone
`.5',._p.;xr;j_ifi&;éi:giuphefaor{é.-U
`Aminofilutethimide
`
`;_§-Jgitnmog§§;t;.it;iu'g§.j'i:¢-_A‘¢ia
`Aminophgllllineu
`I
`
`Amiodaleeue
`
`ff-;§;;gmiitipg§ygjigj§_=__-j._._ :;
`.
`
`I
`
`.
`
`.
`
`'
`
`'
`
`.' _-
`
`:
`I
`-'
`
`__
`
`:
`I
`
`s:
`
`-
`
`'_
`
`-
`
`.
`
`_-
`I
`
`_
`
`._
`I
`
`-
`
`I
`
`'_;i
`
`‘I
`
`"
`
`_.
`.
`..».¢'lrat::.r.1Li_(:JonicAcid-H.
`
`__
`
`.
`
`H
`
`In
`
`H
`
`_
`
`I
`
`SA- 104
`
`B-60!-19
`
`-SB-167
`SG-118
`
`.s..aor_49
`A-60!-16
`
`SD-181
`‘SA-105
`
`= SA-106
`SA- 1 07
`.S.A-108
`SG-281
`
`"B-60;‘49
`B-60l49
`
`A-60146
`B-601549
`B-60!49
`D-SW55
`
`.
`
`33-111
`B-60!49
`SC-125
`C-6052
`-SA.-'109 ' B-60149
`SA-112
`B-60!-49
`
`._s'c-451
`33-112
`
`c-e0r52_
`B-60,49
`
`._-Se-11':
`33-114
`
`_n_.eox'55.
`e-5oxé:9
`
`.'se..'1o'_7_- A-auras:
`SA-131
`e43o:49
`
`.
`
`-_
`
`fS{A%1l213 eB£0»'49]~ I
`‘SHAH-141
`I e—6o;52
`
`}"':Sr‘$.;-'i0‘.‘l‘:. "D.-60155
`"E.‘».l.<-.‘I1.4.
`3950249
`
`-7‘.;SK-‘.115
`I SC.)-461
`
`.B-60_!49'.
`c—eo:52
`
`.-
`
`1
`
`.'S_F-1'11 -'-A-some
`‘SF-.161.
`A-6D:'46
`
`B-QOISD
`
`B—_9o_r5o..
`A-QDI4?
`
`3-9050"
`B-90:-so
`
`A-90M?
`B—90f50
`B-90!50
`D-90£56
`
`3_.9or5o
`C-90.63
`8-90:50
`B-90!50
`
`C-90i53
`B-9050
`
`0:90:56
`3-90:50
`
`_A-‘gum
`B-9{Jf50
`
`D -B-some
`le-99:53
`
`_
`
`-r_1_-90:56.
`B-9.050
`
`_.B§90(5o
`C-90.63
`
`A-90147
`A-QOI4?
`
`-
`
`_
`
`.
`
`-
`
`.
`
`-
`
`_
`
`_
`
`I
`
`22
`
`Astrazeneca Ex. 2044 p. 28
`
`

`
`[S8
`
`350
`
`I47
`
`I50
`
`:4?‘
`
`:50
`
`150
`
`I56
`
`:50
`
`:53
`
`:50
`
`I50
`
`:53
`
`I50
`
`I56"
`
`:50
`
`I47 -
`
`150
`
`:50
`
`:53
`
`I56
`
`:50
`
`:50 __
`
`I53
`
`(4? 5'
`
`I47
`
`ALPHABETICAL PRODUCT LISTING
`
`Dose/'Price Schedules For Matching Placebo Pellets Appear 011 Pages 17-19.
`
`21..Day Release
`C'.a!nf::g Price
`Pin-i1L':i¢IIt-I
`Numi)I:r Paige
`NlIlI'Ih<'-.I'
`
`60-Day Release
`Czilnlasg Prim’
`.Ԥt:l1et|u1L-.F
`.‘€uu1l1crl’:u;;{-
`}\'umh{-r
`
`90-Day Release
`t':It::!ng Prirr
`.“iI.'l1i-(lulu!
`-_\urnlI_::':r
`I-‘age Nmnhc-r
`
`NK~115
`
`C~9D.’53
`
`-Asparagine
`
`I
`
`'
`
`D-Asparlic Acid
`
`';_';';a:'1ic Acid
`
`3i_r¢:pine' "Methyl Bromide
`8—Azaadenine
`
`A A cm
`
`C~BOr'52
`
`C-QCH53
`
`C-60f52
`
`B-60J'49
`
`"A-S0146"
`C-60:'52
`
`C-60:’52
`
`. Bream ':
`
`-
`
`'
`
`'
`
`'
`
`B-60;'49
`
`BI§q,f49_'
`C-60:'52
`
`''
`
`"
`
`'
`
`3
`
`B-60I49
`
`._jA-;es'_t:):é':'e_s'.'_
`D-fi0I55
`
`I meloxsae [
`
`C-fi0!52
`
`':_
`
`.;.;;:
`
`;
`
`C~.‘l0f53
`
`3-9050
`
`- A—.9;§I4?
`C—90r‘53
`
`. c9_b:sa;
`C—9l)r'53
`
`A ; WSOP
`B-SW50
`
`L?
`
`"
`
`c.9o;53e
`
`"B-;_9@.5Q"_
`B-9.0:'50
`
`V ?**99*i‘?'*
`D-Q('J!56.
`
`5~.ID%9o?S3I-PP
`caosss
`
`23
`
`Astrazeneca Ex. 2044 p. 29
`
`

`
`ALPHABETICAL PRODUCT LISTING
`
`DosefPrice Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`Betarnethasone
`
`Be-Idia_1e'
`
`I‘
`
`21-Day Release
`Qltulng l‘riI.‘I:
`.St:hudu[I:f
`Nurllher Page Nunilwr
`
`60-Day Release
`(‘.::la|u;_I, P1'iL'-'3 Sclledulcf
`l\'umhL-r Page Numhur
`
`90-Day Release
`{'_'al:IIr;;:
`l’1‘iri"
`-°1clwI11|1(-I
`.\Iumhu'.~r Page
`=‘*~iun1!n-r
`
`G-191
`
`K-120
`
`L-21:‘B3
`
`se-191
`
`L-GDIS4
`
`NG-191
`
`L-9Dl65
`
`C—21l51
`
`SK-120
`
`C"-SW52
`
`NK-1-20 ' C-90{53
`
`8—Bromoadenosine 3'25’ Cyclic Monophosphate
`
`N-221
`
`M-21r’66
`
`sw-221
`
`M-60-B7
`
`NN-221
`
`M-90168
`
`'
`
`:Bromo_crip‘_u'né Mésylate
`
`C-231
`
`.E-211157
`
`so-231
`
`E-60:58
`
`NC-231
`
`E-QUISQ
`
`5-Bromo—2‘-Deoxyuridine {emu}
`
`N-231
`
`B-21.148
`
`SN-231
`
`B-60!-49
`
`NN-231
`
`B-90.’5O
`
`-Br'ur_:ine' _..
`
`Busulfan (My|eran)
`
`.:__ _caffeine 1
`
`A
`
`Calycanthine
`' "'(i3_iaH1plo_lHecin " '
`
`Caploprtl
`
`-"I-i'C.a1_bamaz'_epihe-_ -_
`
`'
`
`'
`
`_K-122.
`
`z-130
`
`C-2 1 1'51
`
`_sK-1'22
`
`C-6.0152
`
`NK-122
`
`C—90;'53
`
`B-21 1'48
`
`32-130
`
`B-601149
`
`NZ- 130
`
`B-90150
`
`c-191
`
`"C-21/51
`
`50-191
`
`C-601152
`
`N01 91
`
`C-90.153
`
`K-123
`
`B-21 1'48
`
`SK-123
`
`B-601149
`
`NK-123
`
`B-90!50
`
`(3-'1'1'1-.3
`
`E—21l5?.
`
`513-115
`
`E-6053
`
`NC-116
`
`E-90159
`
`C-117
`
`B-21 1'48
`
`30117
`
`B~6U:’49
`
`NC-11?
`
`B-90150
`
`_ C‘.-11'-3
`
`-
`
`C-21!51
`
`so-113
`
`C-601152
`
`NC~113
`
`C-IQUI53
`
`C—4?1
`
`C-21I51
`
`so-em
`
`C~60:'52
`
`NC-471
`
`C-90;'53
`
`-v-"271 '
`
`.c-21151
`
`sv-211
`
`C-60.-'52
`
`NV-271
`
`c-90153.
`
`V-215
`
`C-21!51
`
`sv-215
`
`C-60.-'52
`
`NV-215
`
`090153
`
`'
`
`.\'.‘l'e-ca11_'-cu'.~;ltinII'_'n.1.al<e aay dosezmd any release time, {PLEASE3lNQU_:‘RE}
`sa-110
`NB~170
`A-SW47
`
`B-170
`
`A—21:’45
`
`A—6Ui46
`
`Carbinoxamine
`
`;’,l.J_l;'-'C3a"r1'1it'1f1t'=,'
`B-Carotene
`
`§._.
`
`:-
`
`=i'é'|"’-‘».3"-'_'5’,'T"":-‘I';_‘-:l='_
`Cefadroxil
`
`Cefazolin
`
`Cefoperazone
`L
`
`Cefoxitin
`
`1
`
`1
`
`4
`
`" -Cefaulodin --
`Ceftriaxone
`
`_
`
`'
`
`I
`
`-_
`
`.._B<171'-.
`3-172
`
`.A_-2_1k45
`A—21 .-'45
`
`SB-1?1
`
`A-(._$0f_46 .
`
`93-172
`
`A-SW46
`
`NB.-_1'7'17_ A-'90':'4?
`NB-1172
`A-90:47
`
`-'
`
`_'
`
`:a_l1_73- "
`B-1 "I4
`
`- -A-21145-'
`
`53-173 -
`
`A-60!4.6L
`
`A-21 1'45
`
`SB-174
`
`A-60!45
`
`::NB—'1?3-'
`Na-174
`
`A
`
`-
`
`'."-BJ1-735
`
`A-21-:45
`
`-_.sB-1'75
`
`"A-e_0,=4a
`
`N34 75
`
`B-176
`
`A-21!45
`
`S3476
`
`A-60a’46
`
`NB-1?6
`
`A—9{J.’4'!
`
`. A-90:47 "
`A-QOI47
`
`LB-177
`
`A-21345
`
`"S3477
`
`A-60146 '
`
`NB~'1'7?'
`
`' A-9_0I47
`
`B-1 78
`
`A-21:45
`
`SB-178
`
`A-60146
`
`NB-178
`
`A-90:47
`
`Céntmphe‘n'9xine ('i_»1ecj1tare'n'm§t,é.-1
`
`Cephalexin
`
`"c-115
`
`c-21151
`
`SC-115
`
`C-6DJ'52
`
`NC-115
`
`c-90:53
`
`B-118
`
`B-21:43
`
`SB-118
`
`B-601919
`
`NB-118
`
`B-90!5(J
`
`24
`
`Astrazeneca Ex. 2044 p. 30
`
`

`
`159
`
`1:50 I
`
`353-"
`
`N50
`
`3:532
`
`3150
`
`M59 -_
`
`M50
`
`353
`
`3:53
`
`3153'
`
`M53
`
`RE) _
`
`H47
`
`H47: I
`
`H4?
`
`).*473?'
`
`JM7
`
`J.r47'§'
`
`JI47
`
`3:47‘:
`M47
`
`Product
`
`Cephaloglycin
`
`--h__|;fnr?éfij.t)_mIciI
`Chlorarnphenicoi
`
`A
`
`_' H Efi|__ora_mphen|_co| Base _
`
`Chlorcyclizine
`
`%'j§'Q:_;.1_.1:h;n1_:1aic_lin'c'ane'Acn¥'.-tcfante
`
`Chloroquine
`
`Chlorotrianisene
`
`Egbhiorpheoiyamine _
`
`Chlorpromazine
`
`hlorlhalidone
`
`Chiorzoxazone
`
`1|
`
`liififjfnetidine
`Ilinchonidine
`
`r'::iIi'n'arizine .
`
`Clemastine
`
`Ctomiphene Citrate
`
`ffi_Ip_ran§ine
`
`Clonidine
`
`N50
`
`Ciolrimazole
`
`25
`
`ALPHABETICAL PRODUCT LISTING
`
`DosefPriee Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`21-Day Release
`.'€cIml:1h-A’
`{‘a1::In;_; Flier
`.‘\ umhur
`Ntlnlht-I‘ Pu ge
`
`60-Day Release
`('Tdl:u|u;_-. Prirv .‘.'irimInl:u"
`Namlnr.-1'1’:I;_::-.
`.\-umhrr
`
`90-Day Release
`l";sl:IliI;:-_ Prim: 5r|1I:|!lJ.lL'r'
`T\1IrnI_u-I‘
`I’-::ge Number
`
`B-119
`
`D~2‘U54
`
`SB-119
`
`D~60!55
`
`NB-119
`
`D-90;'56
`
`B—5U:"49
`
`B-90!50
`
`Tom
`
`' "
`
`
`
`c-90153
`
`C-S‘U;"53
`
`C-90!53
`
`C-90!53
`
`._B-60!4.9
`
`c—5o(52
`
`_ ciaorsz
`
`B-SW49
`
`NC-120
`
`C-90f53
`
`'::'-i'_'-.§3¥9D!53;.-
`B-QDISD
`
`j
`
`.
`
`c4_3_o:52
`
`HJaor61
`
`1:150:52"
`B-60.-'49
`
`N_C-i_:1=§' "
`NC—118
`
`I-CE-Q9-X-S-3:
`H~9D1’B2
`
`fig"-.
`IN
`NP-211
`
`'c_..'9'0i53_i
`
`B—90r’50
`
`_ Q-50:52
`3:50:49
`
`_f*!¢"-'1'b3:_3'
`NC-251
`
`=<:e9br53 5
`
`B-90)'50
`
`.B_é£_‘>__0!49
`
`B—60.'49
`
`-Nt_:L1_o_5;_'-.
`NB-126
`
`9Ir9°f5o0;r
`B-90l50
`
`Astrazeneca Ex. 2044 p. 31
`
`

`
`ALPHABETICAL PRODUCT LISTING
`
`21-Day Release
`C'.nt;:lm; Price itirhu-‘lulu!
`Mjmlrt-r P:-Iglz
`f\Im111::r
`
`60-Day Release
`('_‘ul;1I:Ig_; Price:
`.“i:;hu:t]u|c!
`.\|umh(-r i’:1f.u: Nurnhur
`
`90-Day Release
`Cal:1lug{’1'icu Eiclwduluf
`I\l:rnl)L‘r Page Number
`
`
`
`'3
`
`__
`_
`fsorntieostuerone
`
`_
`
`H
`
`__
`
`_
`
`lconiséfie
`
`H
`
`._
`
`If
`
`.
`
`;-
`
`-'
`
`'
`
`_
`
`. _'
`
`.
`
`.
`
`_
`
`._
`
`{-)(.3otinine
`_cop}n,-gifih “[2 g;nz;§p,m.;j-'
`lcrorlnolen
`-'-'_t':ro_!:'aIi=rj:a=_.
`
`--
`
`_
`
`-.
`
`--
`
`SB~12?
`
`B-6U.r'49
`
`NB-127
`
`B-QOISD
`
`I
`
`_-
`
`_'j.f:,=_'s:3_'.1".'5:5-._'._ _;§,4é§1:46-
`‘Niles:-1'35“.-'.".A;:90)'§1f_.:‘
`s¢.3d1
`B-some
`NG-301
`B-90:50 I
`'-.sG—S1_'1_-
`B-66/49'
`N'G_~31-1
`-B§90}50:-I-I
`SG-111
`A-60l46
`NG-111
`A-QUI4?
`1 SG-‘[71
`-' Iuaoms
`ms-17_1_ " A«_9uk47
`SG-121
`B-60f49
`we-121
`B-90150.
`. SG-181
`B-60:49" NG-"181
`B-90!50 3.
`SK- 124
`A-60f46
`NK-124
`A-QUJ4?
`sc-112
`c-50:52
`NC-112
`C-90:53
`so-195
`B-SW49
`NC—195
`B—9G;‘5O
`‘SK-125
`B60155
`NK-125
`0-9055
`
`_
`
`_
`
`.
`
`__
`
`_
`
`Cyclizine
`.cyci';$';_':'i?ios_;c;'r.am;de' tcytoxée)
`D-Cycloserine
`
`-
`
`3
`
`__
`
`_
`
`Cyproheptadine
`_CV:R)fpt;§'rc:'ige'-2f\'_cetate
`II-3-Cysieiune
`
`7
`
`-
`
`.
`
`__
`
`" _
`
`-
`
`_
`
`.'
`
`'
`
`..
`
`;_
`
`_'
`
`D-Cystine
`
`'
`I Cytarabine (Cymsine Arabinoside)
`G§r_tisiz_'1_'e__'__'.'_
`_:'
`1;"
`"i
`_
`
`_'
`
`'
`
`_.
`
`.
`
`_°
`
`-
`
`Cytosine
`_
`'_
`-'§anazoI__'
`Dau norubucine
`
`.
`
`'
`
`'
`
`-
`
`so-103
`I 32.15:)
`SB—128
`"SC-382
`
`sc—431
`so-114
`SQ~201
`_so—211
`50-221
`.'Scz~23-1
`SZ-160
`'SK—12é
`
`SN-241
`SP-251
`32- 1?O
`
`A-«SW46
`-A~60I46
`BJE-W49
`E}-60!55
`
`A-60146
`E-60;‘58
`c-50:52
`c—5o;52
`0-50x55
`C—60;'52
`D—60!55
`Eésorsa
`
`c—5o:52
`D-60:55
`H-6OJ'61
`
`NC~108
`NZ-150
`NB-128
`NC-382
`
`A-QOI4?
`A-902'4?
`B-90150
`D-90!56
`
`NC481
`No-114'
`NQ~201
`-NQ~21_1
`NO-221
`NO-231
`NZ— 160
`NK~126
`
`A-90147
`E~90!59
`c-90:53
`-- c-96:53
`D-90:56
`"c-90;/53
`D-90!56
`E-90!59
`
`NN-241
`NP-251
`NZ- 170
`
`c-90:53
`D«90!56
`H-90362
`
`Astrazeneca Ex. 2044 p. 32
`
`-
`
`—
`
`"
`
`I
`
`'
`
`26
`
`

`
`ALPHABETICAL PRODUCT LISTING
`
`Dose:’Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`21-Day Release
`l_':1t:|lug 1’r"JI.'u
`9-ichn-t.lLJIw"
`_'\|um1Jur
`I’:-‘I-.11: Mnuilwr
`
`60-Day Release
`LTasla1::g_'
`I’r'm_'
`.'-‘win-dlI1u'
`Nmnber‘ l":':ge Nunlhz-r
`
`90-Day Release
`l_'.uI:IIu:_.'{ I‘J'iu.‘t' Scln-.dL|k-J
`N1un|.Ie1'
`l’eI::I_-
`\mmu:r
`
`N-251
`
`B~21f-18
`
`NN-251
`
`B-90150
`
`ND-112
`
`B-90f50
`
`I C—21!51
`
`NV-261
`
`C-90:’53
`
`3.21% I
`
`I
`
`I
`
`B-60}-19.
`
`H
`
`HNHA-1-11
`
`B«90!5U'
`
`I D-601’55
`
`I A
`
`B-60149
`
`B-60:‘49
`
`A
`
`cs;eo:52s 3
`B-60:‘49
`
`Ai6£J;46-
`B-60349.
`
`tigézokssj.-'
`
`'_
`
`I
`
`_
`
`D‘5_°’5§__
`t>+f6ors5~; }
`D-60.-’55
`
`L5-.s_c'u'55
`
`L-60:'64
`
`'
`
`.81-6_0Ii_1Q:":
`B—60I49
`
`;-' c;sp:Sj2 "
`C-60352
`
`.
`
`-
`
`--_'o'2'1k51_-
`B-21!48
`
`Aé2'1!45'.-
`B-21{48
`
`'
`
`.
`
`:' D--21'_;(54- '
`D-21!54
`
`"
`
`.'
`
`.'[i21:54E_---
`
`D-21:'54
`
`"
`
`"D"-21'.’-54:
`L-21.’63
`
`' B—21'r43 f
`B-21f48
`
`_c:—21'I‘5_‘1_ :
`
`c-21:51
`
`L-90365
`
`NB-156
`
`B-90!50
`
`NE-191
`
`C-90:"53
`
`Decamethonium Bromide
`
`'- 3'
`
`"f{e§géffiin_e*Més_yi.éte ;:_-
`W7--I'Jehydrochoiesterol
`fii%.drui=.“"fi'i6.;IF\¢'dL'
`
`A
`
`Dehydroepiandrosterone (DHEA)
`J3 -.'=
`___mi_teepiand,r§sxero'hé'Aqé1été
`
`:_
`
`Dehydroepiandroslerone Sulfate
`_'
`.D_e'hyd'ropreQnendlo_ne"'
`
`16-Dehydrop regnenolone Acetate
`
`If':_§-15$-Dehydroprogesterone
`
`Demeclocycline
`Beoxycholic Acid
`
`Deoxyconicosterone (noc)
`:'D_é‘o'xyconicosterone Acetate (boom
`
`Desipramine
`
`£}es.oximetaso'ne
`
`Dexamethasone
`
`‘ fexame_tf1asone'21"-Acetate
`
`Dexarnethasone 21-Phosphate
`Eiiavendirie
`.
`H 'N“-03—DibutyryIadenosine-
`3._’:5'-C_ycIic_ Monophosphate
`|j'ieiefenac'_
`
`Dicloxacillin
`
`Ei.ierie.s1'ro__|
`
`'
`
`Dienestrol Diacelate
`
`Astrazeneca Ex. 2044 p. 33
`
`

`
`ALPHABETICAL PRODUCT LISTING
`
`DosefPrice Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`21~Day Release
`l':Il-alng Prirl‘ Snshulillt-.-’
`!\uml.n:r Page
`\1:mhcr
`
`60-Day Release
`I‘-.1I;1Eng Prim"
`."i1'l1H|u|t!
`.V1I:I1hI:rl’:1gc
`.Vml1h('r
`
`90-Day Release
`3'\'I:l1I_'tlu|I.-I
`(.‘;IlaTn;;
`i"riL‘t'
`.\umba.-r
`;\'1m:!.:I.'-r
`I';I_'.;I.‘
`
`E-151
`
`B-21343
`
`SE-151
`
`B-60!49
`
`NE-151
`
`B-90350
`
`..C—2.?1.
`
`_
`
`B—21f48
`
`'
`'éc3!2?.ri
`
`.;'.1§_;'_.';_°,»q_;z_1"_«:'a_'_-\::
`B-50r'49
`
`A~c—'27A1 A
`
`A
`
`152:7}
`
`I
`AE%60r58L
`
`B+9§nr5'.
`Iééfioksd
`
`E-i9!J.{"S§?";7
`
`Diethylstilbestrol (DES)
`
`I
`
`" I
`smZ§‘.n;Ia;;teg¢;gi¢;oagI
`_
`E5439 Canuolied Subswtnea PH)! 81
`I I
`I
`A
`A A
`;_-zsaetmu-aruahsxuusnaniéesvéfiafii
`I 513'-I?'r'ir:'.3r::J.rtItIastosterone
`
`.
`
`'_A_-_.1_6'1
`
`_“A_.-.2_1i45 _. sA.-"151
`
`-
`
`A-60;’4£_i.'
`
`_
`
`-:=N'»¢¥-151
`
`Special Dosing For lmmuno-Deficient Mice- See pages 78-80
`-A-_9or.47__
`D-90356
`
`D-106
`
`D-21.354
`
`SD-1 06
`
`D-60!55
`
`ND-106
`
`"I
`
`11:3.j5%r§iLi¢q¢L;%bL+r::yr¢LmAneAA ~ "
`3:5.-Diioldcln-L-Thyronine
`
`9,10-DimethyI—'1.2~I3enzanthracene
`A
`A A
`
`f -_=T.-231
`7-241
`
`0205
`I 1111'?
`
`3 01-101
`
`'B'—2_;1!48-
`
`_
`
`'_3T- 231
`
`B~60!49
`
`NT- 231
`
`B-90'!50
`
`B-21.348
`
`ST— 241
`
`B-60!49
`
`NT- 241
`
`B-90f50
`
`C—2_’] 1'51
`
`- sc_:~2o5_
`
`oaozsz
`
`NC-205
`
`C—90."53
`
`A—21.-'45
`
`SD-117
`
`A-60!46
`
`ND—11?
`
`A-BUM?
`
`I3-21148
`
`7 so-101
`
`s—eor49
`
`ND-101
`
`B.-90f50
`
`D-102
`
`c-21151
`
`SD-102
`
`c-50:52
`
`ND-102
`
`C-QOIS3
`
`
`
`
`
`.
`
`;
`
`;_' C4500-
`
`B—21!48
`
`so-500
`
`B—60!49
`
`NC-500
`
`B-90{50
`
`ND-109
`
`C-90353
`
`Dipyrone
`9.7.5.’-Ii?-‘i’|5-‘Y-"=="'5“F5-9."
`w“|IJi_sul.Iir.ar.n
`
`-I-'I§L-Dofia
`
`In
`
`I
`
`I
`
`Dopaniineu
`
`o5g§¢§c:sne A
`
`D'ro'1.‘e..>r1.ine
`
`mag
`
`c-21'r51
`
`S0409
`
`c-50:52
`
`"
`
`-_'c.~5o_1 '
`(24502
`
`' _B~2'1_;43'.
`c-21:51
`
`S0501
`
`B£0!49
`
`NC-501
`
`B~.90l50
`
`sc-502
`
`c—5o;52
`
`NC-502
`
`C-QOIS3
`
`' C-5031
`
`C"-21251
`
`sc-503
`
`c‘-50:52
`
`NC.-503 .
`
`C-902'53
`
`C-151
`
`C-21!51
`
`sc—i51
`
`C-BOI52
`
`NC—151
`
`C—90r‘53
`
`C4325.
`B-168
`
`.
`
`I
`
`'B,2_;1'r4_a-_'.
`
`s'c—.3_25 '3
`
`A-21 I45
`
`SB- 168
`
`B£0f49
`A-some
`
`NC-325_
`
`NB-168
`
`B-_9_0!50 '
`A-QOI47
`
`I I Z_-
`0403
`
`3:c—2i1I51'
`
`'- SC-504"
`
`tpeorsz
`
`-NC~504
`
`C-90!53 ‘
`
`c-21x51
`
`30-103
`
`cJao;52
`
`ND-103
`
`090153
`
`Dropropizine
`
`Econazole
`
`.
`
`
`
`.
`
`_:D_-1._0_4
`
`0-105
`
`5
`
`gs.-—.2_1;_45-i
`c-21r51
`
`Sp‘-"104
`so§1b5
`
`A_—6.o._r4e
`
`‘ND.-104
`
`045052
`
`ND-105
`
`A-90:47 _
`C-90!53
`
`E-1:03
`
`3-131
`
`H-2_1i6_D'
`
`-
`
`.sE_-103
`
`' H~EU!61
`
`NE?103
`
`H-90362
`
`B-21!48
`
`SB-181
`
`B-60.-'49
`
`NB-181
`
`B-90.550
`
`28
`
`Astrazeneca Ex. 2044 p. 34
`
`

`
`ALPHABETICAL PRODUCT LISTING
`
`DosefPrice Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`Product
`
`Edrophonium
`
`21-Day Release
`('_'.al:I|u_:; E"riu\~
`3L"I|tt!u1L'.F
`.\JuIn|_':('r
`l":t<,;c
`|\'UIl}hl."l'
`
`60-Day Release
`l_‘:Il-.III1n:_; Prim:
`.‘iL-III;-{|u'Ix-I
`_'\'um|Jer
`l’:|;_Ic
`.\.un1hI.-1'
`
`90-Day Release
`Ca::Ilu:_: Price Sc!1u:1lIlle:'
`_\'un1|u-I‘ Pu g-3 Number
`
`C-122
`
`A-21!45
`
`SC-122
`
`A-60:'46
`
`NC-1 22
`
`A-QDI47
`
`n T -
`
`3."-~
`A‘ lEpi_r_1ine(Deoxye;:-inephrine)
`
`SC—201
`
`SC-141
`
`SE-21.1.
`
`- SEQ"-223:1.
`
`._'
`
`,:~./_\.,.-13
`
`pescussg
`D-60:"55
`
`fi:f*3
`
`SV- 291
`
`C-60352
`
`-
`
`"SB"-1.30-_'
`
`B"-60149 3-‘
`
`SE- 101
`
`B-60149
`
`SE--1'02
`
`-_C-60r‘52 ..
`
`"
`
`SK- 129
`
`B-60.’49
`
`SE-131
`
`D-60.355 '
`
`'
`
`C-90.)'53
`
`D-90156
`
`D-90.-'56
`
`C-90153
`
`-
`
`. 3-90350.
`B-90150
`
`' ($90153.
`
`B-90350
`
`D-9056
`
`Special Dosing For Immune-Deficient Mice. See pages 73-77.
`
`E-121
`
`B—21l48
`
`SE~121
`
`- B.-60149
`
`' NE-"121
`
`' B-90350
`
`E-271
`
`B~2114B
`
`SE-271
`
`I3-6Df49
`
`NE-271
`
`B-90.-'50
`
`E-281
`
`B-21;4a
`
`E-291
`
`B-21MB
`
`E-301.
`
`B"-21:45
`
`E-311
`
`B-21:43
`
`_ SE- 2.3.1-
`SE—291
`
`S_E_-30.1 '
`SE-311
`
`I3—60r49
`
`N E-281 '
`
`B‘-90750
`
`B-6Df49
`
`NE-291
`
`B-9050
`
`B-60149 '
`
`NE-3t')_'1 _
`
`B-90_!50 -
`
`B—6U.’49
`
`NE-311
`
`B-90!5D
`
`__ E-32:1 --
`
`‘I
`
`B;-21143“
`
`?s_E-321
`
`B-60f_49 _
`
`- NE-3'21
`
`B-9ok5_o_
`
`1:;_*T_2;,
`
`1?[L-Estradio|+Progeslerone {See Page 39)
`Propiohate '
`l3~Estradiol 17-Valerate
`
`'
`
`'.Ij.§60k55 :
`
`B-SW49
`
`D—9o}'5s'
`
`B-90350
`
`Astrazeneca Ex. 2044 p. 35
`
`

`
`ALPHABETICAL PRODUCT LISTING
`
`DosefPrice Schedules Fur Matching Placebo Pellets Appear On Pages 17-19.
`
`21-Day Release
`(.'£l1.'iIU}_', Price Scheilulu.-.'
`.‘-lumlaer
`|‘:1{.:i.‘ Nunlbur
`
`60-Day Release
`(‘ululug I‘I'iue SL'I1ed11lw'
`.'\lIJn|Ier i’:Ig;;e
`§\.'1rmI.N.-r
`
`90-Day Release
`Calznhrg Price .‘§L‘IIL-Llulir.-'
`|\iI:m11url’:1;_=e
`_\'-umhur
`
`Estriol
`
`Estriol Triacetate
`
`1"."-'r_s_str'ohe':'
`ESIZFCIHE Acetate
`
`E-‘I41
`
`B-21148
`
`- " _' -E-'_39'1
`
`
`
`E-401
`
`A-21M-5
`
`‘
`
`'Ee'1.11.i: I
`
`E-411
`
`.3."-:é'1}4a_
`B-21148
`
`B-60f49
`
`D-'60!l35'_
`A-50:46
`
`B—6D!49 ':_
`B-BOMB
`
`I'_'E-§tr6;s=e H'emi_sup¢i:iate.
`
`' "
`
`'.
`
`ET4-21
`
`"D-21154?-
`
`"D~60!55 I
`
`Estrone 3-Methyl Ether
`.E's'tro.fle3”-Sulfele
`
`.
`
`Ethacrynic Acid
`"-'__I2"th5i_1j13tau't'¢:I_'
`_
`Ethisterone
`
`' "
`
`'1' Ia-Eth'y'_ny'I_est_ra'adio:
`
`Eucatropine
`
`E-261
`
`B-21MB
`
`I E-43.1 '
`
`“
`
`.A-21145"
`
`D-131
`
`c~21r51
`
`73-131-
`
`<3.-21:51
`
`P-191
`
`B-21;4a
`
`.;'E—241-
`
`B-21143 '
`
`K-1 30
`
`D-21.’!-‘:4
`
`M-1-3-1
`
`B-21:48
`
`e«eo;49
`
`A-50:45
`
`C-60;‘52
`
`-go-_5d/S2
`
`B-BOMB
`
`B-6D!49. '
`
`D-60;'55
`
`B-$U_i49
`
`B-90350
`
`. _D-9656".
`
`A-90:47
`
`B-9.0350".
`
`B-90:50
`
`D-90f"56
`
`B-90f50
`
`' A-QOI47
`
`C-9U!53
`
`"C-90153"
`
`B-90!50
`
`B-9'ox5'o
`
`D-90I56
`
`.a—9or5o
`
`-
`F-luE1.£o_E:Or1is<_3'ne.
`Fludrocortisone Acetate
`
`'F_ILffen_aEnic_-Api;:.."-1";
`
`-
`
`3
`
`Flumequine
`'-i;-F1fi.ri;em'a§ors.ef-j 5 -' .3-
`Flunarizine
`
`'
`
`I
`
`Fluocinolone
`
`M-1?1
`
`a-21:43
`
`"_>'<-11.5 "
`
`C-21151 '
`
`F-103
`
`c-21:51
`
`‘ F.-10.4 '
`C-206
`
`L-2'1?-zs_:3-'
`c—21rs1
`
`'
`
`-3 f;'q='..'—1:'t:2 "
`
`' D-'21r'5'4_
`
`F-107
`
`D-2‘H54
`
`I5_.,,5§l5[uE5}b'lI_fale_I:I
`
`'
`
`" 5 I
`
`_
`
`.B-21_!4_B_'_ '
`
`F Iuoxyrnesterone (See Controlled Substances Page 31
`.,’E¥u‘_h.héhazene
`A
`A
`
`A
`
`‘
`
`Flurbiproten
`
`-'FIfita'rfiide"_'
`
`Folic Acid
`
`A-241
`
`A-21x45
`
`F-105.
`
`-
`
`c-21:51
`
`)(-1 25
`
`:3.21.=43
`
`A452
`
`3.21143
`
`V-301
`
`c.21r51
`
`B—60f49
`
`‘C-SW52 '
`
`C-SW52
`
`I
`
`L_'-6oxe_4'
`C-60.552
`
`'
`
`_
`
`D"-'60}!55..
`
`"
`
`D-SW55
`
`3.60349.
`
`._:
`
`A-60:'46
`
`C_-60I52 '
`
`B-6{}!49
`
`B—60.’49
`
`C-60.r'52
`
`3-90:50
`
`C-_90»’_53
`
`c-90:53
`
`L-éox65-
`
`c-90:53
`
`_. D'.-§5)!5B '.
`D-90156
`
`f
`
`= _.-5-Qpxso
`A-90a'4?'
`
`_c-90153
`B-90!50
`
`B-9'0:’50
`
`C-QOI53
`
`Astrazeneca Ex. 2044 p. 36
`
`

`
`ALPHABETICAL PRODUCT LISTING
`
`DoselP1-ice Schedules For Matching Placebo Pellets Appear 011 Pages 17-19.
`
`Folinic Acid
`
`..{..
`
`Furosemide
`
`H Gentamicin Sulfate
`
`21-Day Release
`C3l::'Iu;_; 1‘:-ire
`5chI.'{I.uiL-I
`F\'1:nmn_-rl’:'1;',(.-
`.\‘nInhvr
`
`60-Day Release
`(_‘.:1m1ug I’;-iI:(' Se1n:r.I tale.“
`E\'I1mh1?r|’:|gr Nun1[Irr
`
`90-Day Release
`(_'.:Il:1in,-.5 PI"I1'e 5('I1edu|('!
`'.-‘\IuI11hu_-3' 15:1“
`T\'um|n-I"
`
`V-311
`
`D-21154
`
`SV- 311
`
`D-SW55
`
`NV-311
`
`D-Q0:'56
`
`C-90.’53
`
`3-90x50
`
`cl:-0053 I
`
`A-9034'?
`D-90:556.
`
`' c-90:53
`
`D-90:55
`
`c-90153
`
`3-90;50
`
`c-9053
`
`c-90x53
`
`c-90:53
`
`D-90f5Ei
`
`A-9014?
`
`c-90:53
`
`B-90:50
`
`c-00:53
`
`N-90171
`
`c-90:53
`
`C-90.’53 '
`
`C-90f53
`
`05049
`
`
`B-60.*49
`
`"_. 3.E$$0J55'_3_"
`
`C-6U:'52
`
`'_ '_?Aéac"04s'_-_‘
`
`'
`
`D-BOIS5
`
`C-50:52
`
`D-SW55
`
`c-00:52
`
`B-60!49
`
`c-50152
`
`c-50:52
`
`c-50152
`
`D-60155
`
`A-60:46
`
`C-SW52
`
`B-BOMB"
`
`C-SW52
`
`N-EUITO
`
`C-BOIS2
`
`C-B0!52
`
`C-60:'52
`
`31
`
`Astrazeneca Ex. 2044 p. 37
`
`

`
`
`
`ALPHABETICAL PRODUCT LISTING
`
`Dose.~‘Price Schedules For Matching Placebo Pellets Appear On Pages 17-19.
`
`21-Day Release
`[".iI:|lug I-‘rice
`I‘-ichwllult-.I'
`1Nu:11lIer
`l’u;:I.' Nmuhrr
`
`60-Day Release
`(‘:1!:I|ug Prire .H‘:'lII.-tluln-J
`N1:I11I}cI‘l’uur
`.\«'uml1L-1'
`
`90-Day Release
`C'.ll;!Iu;_: Priul: Sulmlullsf
`.\JumI;er
`I’u<,:c Number
`
`Haloperidol
`
`' ".“Ha'rif1'aI‘;ne'
`
`-
`
`-'
`
`_
`
`-
`
`Harmalol
`
`.. Harrn'an'e'
`
`'
`
`Hannine
`
`'_
`
`-.Hai:rj1§¢'Ii
`
`'
`
`Hecogenin
`
`I
`
`- He't;o{ge'rI:in' Acetate
`
`Hexestrot {Dfhydrn—DES]
`
`I I:fi's_temine"'j' _--
`D-Histidine
`
`-L4H?Sl'idFUe'i-
`
`Homatropine
`
`B-60:’49
`
`' B-6_'OI49'
`
`A-60345
`
`- A-60:46 -
`
`-
`
`B-60I49
`
`A-60.'46
`
`B-BOMB
`
`B~BU!49
`
`C-SW52
`
`C-60:'52
`
`D-60f55
`
`C-60:"-52 I
`C—60f52
`
`"C-6.0r‘.52
`
`B~90{50
`
`B-90.-‘S0 _
`
`A—9or47
`
`F A_-90:47
`B-90f50
`
`A—9o:4?
`
`eeorso
`
`B-90:59 _
`
`C-QOIS3
`
`c—9or53_
`
`0-9055
`
`c-96:53
`
`c-90153
`
`c-90153
`
`Hydra|azj_ne-.
`
`'
`
`Hydrochlorothiazide
`
`H1'@f0°§‘fli_S°.flé -'
`
`'
`
`.
`
`Hydrocottisone 21 -Acetate
`H,;¥d,r<i!c_iir;ii.srsn5e 21‘%H?‘§i$'J§6_ina:e -.
`
`'
`
`- "
`
`Hydrooottisone 21-Phosphate
`'
`
`6-Hydroxydopamine
`
`
`1 105-Hydroxyprogeslerone
`
`.~1'?_b=>H:¥dFWP?995§'terPfie. A
`
`5-Hydroxy-L-Tryptophan
`
`I Hydrexy_u'